Igniting Hope, Breaking Barriers
Our mission is to build a flexible platform for therapeutics cancer vaccines to significantly improve outcomes for patients.
Our vaccine platform is faster, more cost effective, and more versatile than other cancer vaccine technologies.
Irazu’s Membrane Vesicle Platform Technology
Our MVP vaccine platform uses Outer Membrane Vesicles (OMVs) as cancer vaccines
Our proprietary, attenuated bacteria are engineered to produce OMVs bearing tumor antigens on their surface. These antigens are displayed and delivered to sites of immune response to stimulate the body’s own immune system to attack and destroy tumor cells.
Our OMV vaccines are:
Quickly designed and produced at a low cost
Customizable with plug-and-play antigen cassettes
Applicable to a broad range of solid tumors
Size-selected to facilitate uptake by lymph nodes
Self adjuvanted
